The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey by Newbronner, Elizabeth et al.
This is a repository copy of The health and quality of life of Thalidomide survivors as they 
age - Evidence from a UK survey.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/141543/
Version: Published Version
Article:
Newbronner, Elizabeth orcid.org/0000-0003-2366-9981, Glendinning, Caroline, Atkin, Karl 
orcid.org/0000-0003-1070-8670 et al. (1 more author) (2019) The health and quality of life 
of Thalidomide survivors as they age - Evidence from a UK survey. PLoS ONE. e0210222.
ISSN 1932-6203 
https://doi.org/10.1371/journal.pone.0210222
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
The health and quality of life of Thalidomide
survivors as they age – Evidence from a UK
survey
Elizabeth NewbronnerID1, Caroline Glendinning2, Karl Atkin1, Ruth Wadman1
1 Department of Health Sciences, University of York, York, United Kingdom, 2 Social Policy Research Unit,
University of York, York, United Kingdom
* liz.newbronner@york.ac.uk
Abstract
Background
In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a
non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for
morning sickness, Thalidomide caused serious damage to the unborn child. Much has been
written about the drug and the birth defects it caused but evidence about the health of Tha-
lidomide survivors as they age is limited.
Aim
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors;
document the health problems experienced by them as they reach their mid-50s; and exam-
ine the impacts on their health-related quality of life and employment.
Methods
A health and wellbeing survey of 351 UK Thalidomide survivors, which gathered information
about home and employment circumstances, recent health problems, and health related
quality of life (using SF12 Health Survey). Overall analysis focused on descriptive statistics;
the association between respondents’ health related quality of life and original impairment
was examined using Pearson Correlation; and a three step Hierarchical Regression was
used to explore the influence of five factors which narrative responses suggested might be
important.
Results
As Thalidomide survivors reach their mid-50’s they are experiencing a wide range of sec-
ondary health problems, in particular musculoskeletal problems, and depression and anxi-
ety, with multimorbidity a growing issue. These health problems are having a negative
impact on their employment (two fifths are unable to work) and their physical health related
quality of life, which is significantly poorer than the general population.
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Discussion
Having lived relatively independent lives, many Thalidomide survivors are now having to
adjust to growing disability. The study provides further evidence of the accumulative impact
of disability over peoples’ lifetimes and highlights the value of a life course perspective in
understanding the complex experience of growing older with a disability.
Introduction
In the late 1950s and early 1960s the drug Thalidomide was marketed across the world as a
non-addictive tranquilizer. Despite being given to pregnant women as a safe treatment for
morning sickness, Thalidomide caused serious damage to the unborn child when taken during
the first trimester. Much has been written about the drug and the birth defects it caused but
evidence about the health of Thalidomide survivors as they age is limited. The wider literature
on the experience of ageing with disability also remains relatively sparse, although there has
been growing interest in the past decade, in part because the number of people with early
acquired disabilities who are reaching mid and later life is increasing.
The aim of this study was to: explore the health and wellbeing UK Thalidomide survivors;
document the health problems experienced by them as they reach their mid-50s; examine the
impacts on their health-related quality of life and employment; and, where possible, make
comparisons with the incidence of similar problems in the general population, and with
research on Thalidomide survivors in other countries. By focusing on an identifiable group
who are ageing together, the study was also designed to contribute to the wider understanding
of ageing with early onset disability.
Our findings illustrates the challenges of ageing with lifelong impairments, particularly the
interactions between original, congenital impairments and subsequent ageing processes. They
shows the compounding and accumulated impact of impairment and ageing, in which the bio-
logical connects to the social, thereby exposing individuals to environmental factors that fur-
ther generate the potential for disadvantage and social exclusion [1]. These include access to
paid work and self-care, previously characterised by high levels of personal independence. As
former adaptive mechanisms are compromised, new experiences of disability arise [2].
Background
Between 1958 and 1961, Thalidomide was widely prescribed in the UK as a safe, none addictive
sedative and tranquiliser. It was manufactured by a German company, Chemie Gru¨nenthal,
and distributed in the UK by Distillers Company (Biochemicals) Limited. Despite being mar-
keted as an entirely safe treatment for the discomforts of pregnancy (including morning sick-
ness), Thalidomide caused serious damage to the unborn child when taken during the first
trimester. Depending on the timing and level of ingestion, foetal damage typically included:
• Missing, shortened or malformed upper limbs–ranging from complete absence of the arm
(upper limb Amelia) with one or more digits attached directly to the shoulder, to short or
missing long bones and missing or damaged thumbs and fingers
• Shortened or malformed lower limbs–including short or missing long bones, congenital dis-
location of the hip, club foot, and extra toes
• Eye, ear and facial damage–these are the second most common group of birth defects and
include missing or damaged ears, narrow ear canals, small or damaged eyes, restricted eye
movement and facial palsy
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• Malformation of internal organs–such as damage to the heart, urinary and alimentary tracts,
and reproductive organs [3].
Together, these birth defects are referred to as Thalidomide Embryopathy or Thalidomide
Syndrome.
Thalidomide constituted a major medical safely scandal and has, in Sarah Ferber’s [4] words
become “emblematic of the advance then shocked reversal of the optimism of the ‘pharmaceutical
revolution’ of the mid twentieth century” (p133). In the UK it prompted extended public cam-
paigns by the Sunday Times newspaper and the parents of UK Thalidomide-damaged children
for recognition and compensation. It led to global changes in the way in which drugs are tested
and regulated [5], and in the UK to: the establishment of a Royal Commission on Civil Liability
and Compensation for Personal Injury; changes to definitions of contempt in civil law cases;
and a Law Commission report and legislation on civil liability in ante-natal injury.
A charitable trust—the Thalidomide Children’s Trust (now the Thalidomide Trust–see
www.thalidomidetrust.org), was established to oversee compensation payments from Distillers
to the families affected by Thalidomide in the UK. Individual payments were determined
through assessments of level of impairment, with points being given for different types and
severity (totalling from 3.5 to 75 points). The Thalidomide Trust continues to distribute
annual payments from the global company Diageo (successor to Distillers) to all UK born Tha-
lidomide survivors. An elected beneficiary National Advisory Council (NAC) advises the
Trust. Subsequent campaigns by Thalidomide survivors themselves have focused on the UK
Government’s ill-judged licensing of the drug, which had not been adequately tested. In
response, in 2010 the Departments of Health (DH) in England, Scotland, Wales and Northern
Ireland began paying an annual Health Grant to Thalidomide survivors, in recognition of their
growing health and health-related needs. The DH grants, which have been agreed until April
2022, are also administered by the Thalidomide Trust and distributed annually in line with the
severity of initial impairment.
Compared to Thalidomide survivors worldwide, UK survivors are relatively unusual in that
their families, (and now they themselves) have received compensation payments from child-
hood. The level of this compensation has increased significantly over the past decade, as a
result of both increased payments from Diageo and the DH Grants. This should offer a degree
of protection against the disabling consequences of impairments [6]. In other countries com-
pensation arrangements have been much poorer. In Canada for example, when an out of court
settlement was reached between Richardson Merrell and 26 families, the company imposed a
strict secrecy clause, which resulted in wide disparities in compensation amounts for individu-
als with similar levels of impairment [5]. In Spain Thalidomide survivors have never received
any compensation from the company that made the drug. However, in 2011, after a long cam-
paign by Avite (the Spanish Thalidomide group), the Spanish government did make a small
payment to 23 Thalidomide survivors; a fraction of the number believed to have been born in
Spain [7].
Ageing with Thalidomide Embryopathy and ageing with disability
The combination of impairments experienced by many Thalidomide survivors (particularly
limb difference) is rare, and the historical, social and legal context of their experience is
unique. However, because they are such an identifiable group who are ageing together, com-
paring the similarities and differences between their experiences of ageing with those of other
groups with early onset disability may offer new insights into disability and the life-course.
Evidence about the health of Thalidomide survivors as they age is limited [8]. In particular,
few studies have explored the interactions between original Thalidomide impairment, newly
The health of UK Thalidomide survivors as they age
PLOS ONE | https://doi.org/10.1371/journal.pone.0210222 January 16, 2019 3 / 17
emerging secondary damage and co-morbidities. There has also been little attempt to under-
stand how changes to impairment impact on the disabling experience. In the 2000s, when Tha-
lidomide survivors reached their 50s, more research into the health of Thalidomide survivors,
began to be undertaken. Whilst many studies have a narrow biomedical focus, together they
do suggest widespread age-related secondary damage, particularly musculoskeletal problems
(often related to overuse of ‘good’ limbs) and common mental health disorders, notably
depression and anxiety [9, 10, 11]. These two conditions may of course be related, if emerging
musculoskeletal conditions and consequent loss of function (especially difficulties with activi-
ties of daily living and/or reduced ability to work) place Thalidomide survivors at greater risk
of mental health problems [12].
In the broader field of disability research, the past decade has seen growing interest in the
experience of ageing with disability [13, 14], not least because the number of people with from
birth or early acquired disabilities who are reaching middle and older age is increasing [15,
16]. Several overarching themes emerge from the current literature. First, people ageing with
disability often face particular difficulties such as secondary conditions and overuse syn-
dromes, post onset syndromes (e.g. post-polio syndrome) and a sense of premature ageing. As
Molton and Yorkston [16] note, even in conditions which are regarded as ‘static’ (e.g. Cerebral
Palsy), peoples’ functional limitations can change across the life course, creating further poten-
tial for disability. Moreover, they suggest that “there is now mounting evidence that the cumula-
tive effects of living with a disability condition for many years contribute to premature declines in
health” (p291). Secondly, people experiencing the later life effects of early acquired disabilities
appear to be more at risk of depression and lower life satisfaction [15,17], although there is evi-
dence that poor overall health, rather than the extent of (original) impairments is more signifi-
cant in terms of social isolation [13]. Lastly, people growing older with disability often have an
elevated risk of acquiring age-related chronic conditions [18, 19], which disability may in turn
make more difficult to manage.
Within the disability literature, a few authors [1, 14, 20, 21] have proposed that a life course
approach might provide a productive and more holistic framework for thinking about how
disability affects people at different points in their lives, including ageing with disability. As
Naidoo et al. [14] point out, “age and disability are not defining traits of an individual but over-
lapping phenomena that occur throughout the span of the life course” (p3). Drawing on the prin-
ciples of life course theory developed by Elder et al. [22], they suggest that a life course
perspective brings to the fore “individual choice and circumstance” and locates them “within
larger social and historical context” (p3)
This paper contributes to the literature on ageing with disability by focusing on the experi-
ence of UK Thalidomide survivors. It presents evidence that the health problems caused by
Thalidomide are not restricted to the well-documented neonatal impairments. On the con-
trary, it argues that: survivors are encountering significant new Thalidomide-related challenges
to their physical and mental health and well-being as they age; that these changes in health are
linked to individual choice and circumstance; but also to the social and historical context in
which Thalidomide survivors have lived their lives.
Methods
The UK Thalidomide Trust, which holds details of all those to whom it makes Diageo and DH
payments, commissioned a survey of the health and wellbeing of its 467 beneficiaries to help
develop appropriate support for beneficiaries as they aged. The survey was primarily intended
to gather information to inform the Trust’s work and specifically aimed to:
• Quantify the incidence of beneficiaries’ health problems
The health of UK Thalidomide survivors as they age
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• Examine beneficiaries’ mental and emotional wellbeing
• Investigate beneficiaries’ wider circumstances and anticipated future needs.
Survey questions were developed in collaboration with the Trust’s Research Committee,
Trust staff and NAC. They covered nine main topics: family and housing; work and pensions;
original Thalidomide impairments; mobility and equipment; health problems; use of health
services; social care support; emotional wellbeing; and health related quality of life. This final
topic was explored using the Short Form 12 Health Survey (SF12), a 12-item version of the
Short Form-36 Health Survey Questionnaire, widely used in health research in the UK and
internationally, to measure health related quality of life. This paper draws on the survey data
about respondents’ characteristics and then focuses on two topics—health problems and health
related quality of life. Data on the other topics explored in the survey have proved valuable to
the Thalidomide Trust but are not discussed here.
The self-completion questionnaire was piloted online and on paper with ten beneficiaries
with a range of impairment severity. Paper copies of the final version were sent to all beneficia-
ries in early August 2015 together with an information sheet and covering joint letter from the
Trust Director and NAC Health andWellbeing Committee Chair. Beneficiaries who had pre-
viously informed the Trust they were willing to be contacted by email were also sent the link to
an online version; the option of a telephone interview with a member of the research team was
also offered. One reminder letter was sent and the survey closed end September 2015 with
responses from 351 Thalidomide survivors (75% response rate). Four responses were com-
pleted by family members/guardians on behalf of beneficiaries. Although respondents could
opt to complete the survey anonymously, 87% gave their names, which enabled their survey
responses to be linked to information held by the Trust about their impairment level and
country of residence.
The overall analysis–using SPSS (version 24) focused on descriptive statistics. We also
examined the association between respondents’ health related quality of life and original
impairment using Pearson Correlation, and then used a three step Hierarchical Regression to
explore the influence of other factors, which the narrative responses in the survey had sug-
gested might be important (i.e. step 1—original impairment level; step 2—being unable to
work and qualifications; and step 3—gender and living alone). Multicollinearity checks were
run on all predictor variables included in the models. Where possible and appropriate, the
findings from the survey were compared with the general population of a similar age and/or to
findings from studies of the health of Thalidomide survivors in other countries. Comments
and additional information provided in free text boxes were analysed thematically. This are
not reported here in detail but quotations from these narrative responses are used to illustrate
findings form the survey.
Ethical approval was obtained from the Department of Health Sciences Research Gover-
nance Committee, at the University of UK on the 19 May 2014.
Results
Survey respondent characteristics
Here we describe the characteristics of the survey respondents, in order to provide context for
the results presented in later sections. In the UK and internationally, limb defects, particularly
missing or short arms, are the most commonly recognised feature of Thalidomide damage.
However, damage took many forms and varied considerably in severity. The drug was also no
respecter of class or culture, so survivors are a widely heterogeneous group. Respondents were
evenly split between women and men (174 respectively; three respondent did not give their
The health of UK Thalidomide survivors as they age
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gender). At the time of the survey, the Trust grouped its beneficiaries in to five impairment
bands, with band 1 covering beneficiaries with the least severe impairments and band 5 those
with the most severe. Based on these bands, the distribution of the overall severity of their
impairments was similar to that of all UK beneficiaries (Fig 1).
Respondents were asked to describe their original Thalidomide impairments using 25 cate-
gories covering limb damage, sensory impairments and internal organ damage, plus a free text
box for other damage. For ease of analysis, these were collapsed into eight groupings and their
incidence compared (in aggregate form) with data held by the Trust. This enabled us to check
that the survey respondents were broadly representative, in terms of the range of impairment,
of all UK Thalidomide survivors. For example, the proportions in survey and in the Trust’s
data were very similar for respondents with upper limb only damage (survey 58%/Trust 54%),
lower limb only damage (survey 5%/Trust 4%), and no limb damage, (survey 12%/Trust 11%).
However, there was a difference in the proportion with both upper and lower limb damage
(survey 25%/Trust 34%).
However, because the Trust’s information was collected at the time beneficiaries were assessed
for their compensation claims i.e. from the 1970’s onwards, the survey also provided a more up to
date picture of impairments, particularly damage to internal organs which for many had only
come to light later in life as a result of diagnostic scans. This was reflected in survey results. For
example, 31% of survey respondents said they had damage to internal organs, whereas the Trust’s
data showed just 22% with this type of damage. Thalidomide survivors who were blind or partially
sighted appear to be under represented in the survey. This may reflect the method of data collec-
tion, although large print version of the questionnaire were available and respondent could choose
to complete the survey by telephone. Importantly, the survey confirmed that many Thalidomide
survivors have multiple impairments e.g. 73 respondents had upper limb damage and were deaf/
partially deaf and 27 respondents had both sight and hearing impairments; and almost all respon-
dents reporting internal organ damage also had other impairment/s.
Almost two thirds of respondents lived with partners/spouses or with a partner/spouse and
other family members. Nearly a quarter (76/22%) lived alone (compared to 17% of the general
Fig 1. Distributions of survey respondents and all beneficiaries by impairment band.NOTE: n = 302; it was only
possible to identify the impairment band for respondents who gave their names.
https://doi.org/10.1371/journal.pone.0210222.g001
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UK population aged 50 to 64 [23]; 10% lived with another family member/s (e.g. parents/sib-
ling). Nine respondents lived at home with full-time paid carers or in residential care. The
majority of respondents (304/87%) owned their house or flat, compared to 75% of the general
UK population aged 50 to 64 (75%) [24].
Self-reported health problems
The survey asked Thalidomide survivors about additional health problems, over and above
their original impairments.
Musculoskeletal problems and pain. Almost all (93%) reported musculoskeletal prob-
lems (pain and/or loss of movement in joints, neck and/or back). Back problems were the
most commonly reported musculoskeletal problem, closely followed by shoulder pain/loss of
movement and problems with hands (Table 1). In comparison, less than 20% of adults aged
45–64 in the general population report chronic musculoskeletal conditions [25] and only 15%
suffer low back pain [26]. The prevalence of musculoskeletal problems, particularly back prob-
lems, is therefore higher amongst UK Thalidomide survivors than in the general population, a
pattern also found in Swedish Thalidomide survivors [27]. Many survey respondents reported
multiple musculoskeletal problems, with a mean of 4.5 problems and over half reporting five
or more problems.
Almost half (49%) of respondents reported generalised pain: 26% said this was severe and/
or continuous and a further 23% described it as moderate and/or intermittent. Respondents
with most severe Thalidomide damage were the most likely to report generalised pain. For
some, the cause of the pain was unclear:
“Chronic neuropathic pain in peroneal nerves—both legs, below knee. 5 years. No cause
found. Does not respond to treatment/pain management medication.” (Survey ID298)
“I have been suffering with regular bouts of pain in my side. I have had several tests done but I
am told there is no conclusive reason for the pain.” (Survey ID104)
Two-thirds (66%) of respondents also reported one or more neurological symptom (e.g.
tingling and numbness). Two fifths reported severe tiredness/fatigue; this was more common
among respondents in Bands 1 and 2, possibly because they were more likely still to be in paid
work and therefore less able to rest.
Mental health. Half the respondents said that they were currently or had recently experi-
enced depression and/or anxiety (41% reported anxiety and 34% depression). This is in stark
contrast to the estimated 20% of adults in the general UK population aged 50–54 reporting
common mental health problems (e.g. depression, anxiety or panic) and the estimated 8%-
Table 1. Prevalence of musculoskeletal problems.
Musculoskeletal Problem Number/%
Back problems–prolapsed disc; damage to vertebrae; scoliosis and/or muscular pain 254/72%
Shoulder–pain, loss of movement or deterioration of the joint 211/60%
Hands–pain, loss of grip and/or dexterity 210/59%
Arms and wrists–pain, loss of strength and/or movement 197/56%
Neck pain and/or loss of movement 195/55%
Knee–pain or deterioration of the joint 168/48%
Hip–pain, loss of movement or deterioration of the joint 164/46%
Ankles, feet and toes–pain and/or loss of movement 100/28%
https://doi.org/10.1371/journal.pone.0210222.t001
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12% adults of all ages reporting depression in any year [28]. The prevalence of poor mental
health among UK Thalidomide survivors is also higher than a general population survey of
7500 physically disabled adults (all ages), of whom 19.5% reported depression or mixed
depression/anxiety [17]. However, it is very similar to the prevalence of mental health prob-
lems among German survivors [11], where face-to-face psychiatric assessments found 47.7%
of Thalidomide survivors currently or recently experienced mental health problems.
Hearing, sight and dental problems. Deteriorating sight/eye problems were a concern
for 43% of respondents and 38% (133) said that they had deteriorating hearing/other ear prob-
lems. Although these figures will include normal age-related deterioration, this can cause addi-
tional problems for Thalidomide survivors e.g. having very short arms makes putting glasses
on and off difficult, whilst wearing glasses can be problematic for those with facial damage
(e.g. a missing ear). Thirty-four percent of respondents reported dental health problems. As
with Swedish Thalidomide survivors [29], these problems may reflect difficulties with tooth
brushing and a history of using teeth to grip and hold.
Other health problems. Respondents reported a range of other health problems, with
weight management (n = 141/40%), bowel and digestive problems (n = 98/28%), bladder or
continence problems (n = 72/20%) and asthma or breathing problems (n = 54/15%) being the
most common. Again, these health problems may be more difficult to manage or exacerbated
by Thalidomide damage. A recent Japanese study [30] suggests that hypertension is a particu-
lar concern because of the difficulties many Thalidomide survivors experience in exercising
and managing weight, and the challenge of obtaining accurate blood pressure and body mass
index measurements in people with limb impairments.
Multimorbidity. A high proportion of Thalidomide survivors reported multiple health
problems (see Fig 2). Just 3% had no health problem but almost half (46%) reported between
four and nine separate problems. Multimorbidity or the presence of multiple diseases in one
individual is a growing concern in the UK population as a whole but these results suggest that
a higher proportion of Thalidomide survivors are experiencing multimorbidity than would be
Fig 2. Proportions of Thalidomide survivors reporting multiple health problems.
https://doi.org/10.1371/journal.pone.0210222.g002
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expected at this point in their life course. For example, in Barnett et al’s [31] study of multi-
morbidity in Scotland, around a third of patients aged 55 to 59 had two of more morbidities
but less than 10% had four or more morbidities. Furthermore, for some Thalidomide survivors
the morbidity burden i.e. the overall impact of several conditions on the individual’s “physio-
logic reserve” and functioning [32] is significant. A comment added by one respondent vividly
illustrates this:
“After having operations on both shoulders and left elbow the use of my arms and hand were
considerably limited e.g. dressing, washing, cooking, and most basic household chores. Also
having a mini stroke has made my balance a bit difficult. And then the cancer came along. . .”
(Survey ID21)
The impact of health problems on paid work
These widespread health problems were reflected in survey respondents’ employment status.
Two-fifths (145/41.3%) were now unable to work because of their disability or health problems
(Table 2). Previous research suggests that less than 10% of UK Thalidomide survivors have
never worked [33]. As in the general population, there were significant differences between
men and women: men were more likely to be working full-time; women were more likely to
work part-time; and women were also marginally more likely to be unable to work because of
their disability or health problems (69 men compared to 76 women).
The likelihood of not working increased with the severity of impairment: the proportions
reporting currently being unable to work increased from 35% of those in Band 1 (least severe)
to 75% in Band 5 (most severe); whilst the proportion currently in full-time work decreased
from 32% (Band 1) to 8% (Band 5). Moreover, although respondents in impairment bands 1
and 2 were more likely than their peers with more severe impairments to still be in full time
work, around a third of them still reported being unable to work because of their disability or
health problems. Patterns for those working part-time were less clear.
Comparisons with the general population, and/or with people with disabilities as a whole
are difficult, as different sources use different terminology, definitions and age groupings.
However, in 2015, 82% of the general population aged 50–54 (78% of women, 86% of men)
were in paid work [34] (DWP 2015), suggesting that only 18% of the age group were ‘economi-
cally inactive’, compared to 63% of Thalidomide survivors.
In the UK, disabled people may be four times as likely as their non-disabled peers to be
unemployed or involuntarily out of work [35]. However, the lifetime economic activity pat-
terns of Thalidomide survivors appear to be somewhat different from those of other disabled
Table 2. Work situation.
Work Situation–all respondents Number/%
I’m unable to work because of my disability or health problems 145/41.4%
I work full-time 54/15.4%
I have chosen not to work in order to preserve my health/functioning 45/12.9%
I work part-time because of my disability or health problems 30/8.6%
I work part time in order to preserve my health/functioning 29/8.3%
I work part-time for family or personal reasons 17/4.9%
I’m not working at the moment but would like to 15/4.3%
I’ve chosen not to work for family or personal reasons 8/2.3%
Other (e.g. education) 7/2.0%
https://doi.org/10.1371/journal.pone.0210222.t002
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people. First, their current employment patterns do not reflect the lower levels of educational
achievement which commonly disadvantage disabled people; their educational achievements
were broadly similar to those of the general population of a similar age [36]. The proportion
of Thalidomide survivors with no qualifications was similar to those of working age disabled
people in general. On the other hand, the proportion with degree-level qualifications was
higher than working age disabled people in general [37]. Similar educational qualification pat-
terns have been found among German Thalidomide survivors [11]. Secondly, at each level of
educational qualification, there was a range of severity and type of impairment (e.g. the 19
respondents with degrees working full time were spread across all five severity bands and
most types of impairment). This suggests that whilst respondents’ ability to work was strongly
linked to the severity of their impairment, educational qualifications also had an important
influence. Thirdly, the survey showed that Thalidomide survivors’ work situation had changed
significantly over the last 10 to 15 years. Overall, 207 respondents (59%) reported changes
in their work situation since 2000, with most changes taking place in the last five years (Fig
3). This trend has also been seen amongst Thalidomide survivors in Canada and Germany
[9, 38].
“Increasingly from 2002 onwards, at which time I was a Director of a limited company work-
ing in excess of 50 hours per week. I now struggle to manage 18 hours per week. I have now
reached the point where stopping work altogether is imminent.” (Survey ID2)
Less severely impaired respondents (Bands 1 to 3) were more likely to have reduced their
working hours or changed the type of work they did. Although greater proportions of more
severely impaired beneficiaries (Bands 4 and 5) had stopped working since 2000, this change
had also occurred across all impairment bands. For example, over three quarters of respon-
dents in bands 1 to 4 were working prior to 2000. By 2015, less than half of all respondents
were working and, moving from band 1 to band 5, there was a gradual fall in the proportions
still working.
Fig 3. Changes in work situation since 2000.Note: 15 respondents reported more than one change, so appear in more
than one category; all had reduced working hours and all but one had changed the type of work they did.
https://doi.org/10.1371/journal.pone.0210222.g003
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“2011 I was forced to make a difficult decision to stop working due to continued failing
health.” (Survey ID183)
“In 2009 I had to reduce my hours in line with medical advice. In 2010 I had further
problems. . . and in 2011 I was medically retired (not at my request) as my employer had no
role for me.” (Survey ID276)
Thalidomide survivors’ health-related quality of life
The SF12 Health Survey was used to measure health related quality of life. SF12 consists of
eight scaled sections (General Health; Pain; Physical Functioning; Role Limitation Physical;
Mental Health; Role Limitation Emotional; Social Functioning; Vitality), which can be ‘aggre-
gated’ into two domains: physical health related quality of life and mental health related quality
of life. Of the 351 survey respondents, 335 returned SF12 questionnaires that were useable for
analysis (i.e. no missing data) and for 285 of these we were able to link SF12 scores to level of
impairment (as indicated by the number of impairment points the individual had). Fig 4
shows the range of scores for the survey respondents compared to the general population aged
45–54, based on responses to the Central England Healthy Life Survey [39].
In the physical health domain respondents had a markedly lower average aggregate score
than the general population (i.e. a mean of 26.7 compared to 50) indicating that their physical
health related quality of life is much poorer. 59.7% (n = 200) of the respondents had a score
below 30 i.e. the same as or worse than the 2% of the general population group with the poorest
physical health related quality of life, and only 7.5% (n = 25) of the respondents had a score
above the average for the general population group.
In the mental health domain the average aggregate score for respondents was 46.5, slightly
lower than the general population (score 50). This suggests that on average Thalidomide
Fig 4. Normalised SF-12 physical and mental health scores for survey group.
https://doi.org/10.1371/journal.pone.0210222.g004
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survivors’ mental health related quality of life is only marginally poorer than their peers in the
general population; indeed 40.9% of respondents (n = 137) had a score above the average for
the general population. However, 10.7% (n = 36) had a score below 30 i.e. the same as or worse
than the 2% of the general population with the poorest mental health related quality of life.
Overall men had a higher mean score for physical health (28.6 compared to 24.7) which was
significant (t (327) = 2.567, p = 0.01.). Women had a higher mental health score (47.8 com-
pared to 45.1), which was not significant (t (327) = -1.981, p = 0.05).
We also used the SF12 results to examine whether there was any relationship between
health-related quality of life and level of impairment. We found that there was a strong nega-
tive correlation (r = -.276; p = .000) between lower SF12 physical health scores and severity of
impairment i.e. themore severe a respondent’s Thalidomide damage, the poorer their physical
health related quality of life was likely to be. In contrast, when we examined the same relation-
ship for mental health related quality of life, we found that the less severe a respondent’s Tha-
lidomide damage, the poorer their mental health related quality of life was likely to be i.e. there
was a positive (but weaker) correlation between lower SF12 mental health scores and less
severe impairment (r = .148; p = .012).
The responses to the narrative questions in the survey suggested that other factors, in par-
ticular being unable to work because of secondary health problems, could be important in
explaining variance in both physical and mental health-related quality of life. To examine if
this was the case we used hierarchical regression, using three sets of variables: original
impairment level (as indicated by the number of impairment points) (step 1); being unable/
able to work and qualifications (step 2); and gender and living alone/living with others (step
3). Tables 3 and 4 below show the results for SF12 physical and mental health scores.
The model predicting physical health was significant at: step 1—F (1, 273) = 24.526, p<
.001; step 2 –F (3, 271) = 30.337, p< .001; and step 3 –F (5, 269) = 19.396 p< .001. The results
for SF12 physical show that together the five variables explained 25% of the variance in physi-
cal health related quality of life. However, only three variables make a unique statistically
Table 3. Hierarchical Regression results for SF12 Physical.
B SE B B (95% CI) Sig.
Impairment Level - 0.194 0.063 -0.31, -0.07 0.002
Unable to Work 11.556 1.572 8.46, 14.65 0.000
Qualifications - 0.184 0.290 -0.75, 0.38 0.526
Gender - 3.207 1.471 -6.10, -0.31 0.030
Live Alone - 0.343 1.755 -3.79, 3.11 0.845
Note: Step 1 Adj R2 = 0.079; Step 2 Adj R2 = 0.243, ï R2 = 0.169; Step 3 Adj R2 = 0.251, ï R2 = 0.014
https://doi.org/10.1371/journal.pone.0210222.t003
Table 4. Hierarchical Regression results for SF12 mental health.
B SE B B (95% CI) Sig.
Impairment Level 0.190 0.060 0.07, 0.30 0.002
Unable to Work 5.026 1.497 2.07, 7.97 0.001
Qualifications - 0.355 0.276 -0.89, 0.18 0.200
Gender 2.077 1.401 -0.68, 4.83 0.140
Live Alone 0.974 1.671 -2.31, 4.26 0.561
Note: Step 1 Adj R2 = 0.016; Step 2 Adj R2 = 0.067, ï R2 = 0.058; Step 3 Adj R2 = 0.069, ï R2 = 0.009
https://doi.org/10.1371/journal.pone.0210222.t004
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significant contribution (i.e. p = .05 or less)–a higher level of original impairment, being
unable to work, and gender (being male), predicted poorer physical health related quality of
life, with being unable to work accounting for most of the variance.
The model predicting mental health was sig at: step 1—F (1, 273) = 5.348, p = .021; step 2 –
F (3, 271) = 7.514, p< .001; and step 3 –F (5, 269) = 5.080 p< .001. For mental health related
quality of life, the five variables explained just 7% of the variance in SF12 mental health scores,
with only two variables–lower level of original impairment and being unable to work, making
a unique statistically significant contribution to predicting poorer mental health related quality
of life.
Discussion
Over the past five decades, the lives of UK Thalidomide survivors’ have been documented in
the media. They are (rightly) often portrayed as remarkable individuals who have overcome a
unique range of physical impairments to lead active and productive lives. However, the find-
ings from this first comprehensive investigation of the health of UK Thalidomide survivors in
their early/mid 50s show that in addition to their original impairments, many are now report-
ing multiple secondary health problems and rapid loss of function, thereby creating the poten-
tial for further disabling consequences. The layering of these secondary health problems on to
lifelong impairments is causing many Thalidomide survivors to give up paid work prematurely
(a trend which has accelerated in the last 10 years), and need more help in their daily lives.
From being hitherto relatively independent, they appear to be increasingly out of step with
their non-disabled peers at the same stage in the life course.
Musculoskeletal problems were over four times as common amongst Thalidomide survi-
vors as in the general population of a similar age, and a high proportion experience multiple
musculoskeletal problems. These problems are leading to loss of function and associated diffi-
culties with activities of daily living and for many this is having a negative impact on their
mental wellbeing. This link has been found in other studies of disabled people. Melzer et al.
[17] found that the number of Activities of Daily Living/Instrumental Activities of Daily Living
that people with disabilities had difficulties with, had an incremental effect on the likelihood of
them experiencing depression. The quotation below from a response to the narrative questions
in the survey illustrates this effect in relation to Thalidomide survivors:
“My only normal hand is deteriorating badly. I've had 3 operations on it, they can't do any-
thing more. I'm in pain with it nearly all the time. I can't do hardly anything for myself now.
I'm terrified. I'm only 55 –how much worse is it going to get?Having one hand I was never dis-
abled but I am now. Luckily I have fantastic children who all automatically do everything for
me that's needed. They cut my food up, do up my buttons, zips, and laces, and are amazing
but I don't want to be a burden to them. Losing your independence is soul destroying.” (Survey
ID307)
Alongside secondary physical health problems, half the survey respondents said that they
were currently or had recently experienced depression and/or anxiety. This self-reported prev-
alence of common mental health problems is significantly higher than in the same age group
in the general population and higher than adults (all ages), with other physical disabilities.
However, it is supported by evidence from clinical studies conducted with Thalidomide survi-
vors in Germany.
The prevalence amongst UK Thalidomide survivors of ‘lifestyle’ diseases and other condi-
tions associated with middle and older age is unclear. However, the practical challenges of
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preventing and self-managing conditions such as diabetes, can be huge for people with limb
difference. A high proportion of survey respondents reported the same risk factors for lifestyle
diseases as other people with physical disabilities, notably weight management and difficulties
exercising. The risk for Thalidomide survivors may be compounded by the problems of accu-
rately measuring blood pressure and body mass index when people have missing or short
limbs [30]. Crucially, many Thalidomide survivors reported multiple health problems. More-
over, a higher proportion of them were experiencing multimorbidity than would be expected
at this point in their life course, and for some the morbidity burden appeared significant.
The study also showed that Thalidomide survivors experience significantly poorer physical
health related quality of life compared to the general population but their mental health related
quality of life was only marginally poorer than their peers in the general population. These
findings are consistent with a German study of 186 Thalidomide survivors in North Rhine
Westphalia, which used SF36. Peters et al. [11], reported that Thalidomide survivors had a
mean aggregate physical score of 29.6 and a mean aggregate mental health score of 47.8. A
Swedish study of 31 Thalidomide survivors [40] also found that their physical health related
quality of life was significantly lower than the general population, although their mental health
related quality of life was similar.
Whilst the more severe a respondent’s original Thalidomide damage, the poorer their phys-
ical health related quality of life was likely to be, being unable to work accounted for most of
the variance in SF12 scores. This suggests that secondary health problems and associated loss
of function may be a far more important influence on physical health related quality of life
than original impairment alone. In relation to mental health related quality of life, the narrative
responses to the survey suggest that for Thalidomide survivors with lover levels of impairment,
who have probably been actively employed for most of their lives, having to give up work (as
opposed to choosing not to work) is having a detrimental effect on their mental wellbeing.
However, the quantitative analysis showed that being unable to work accounted for just under
7% of the variance in SF12 scores, which implies that psychosocial factors, not explored in the
survey, may be of more importance.
Studies of the wellbeing and quality of life of people with disabilities [41, 42], have found
that those disabled from birth were likely to have higher subjective wellbeing that those dis-
abled later in life. This study shows that whilst the majority of Thalidomide survivors have
lived relatively independent lives, many are now having to adjust to growing disability. For
those with mild to moderate impairments in particular, the experience of this change appears
to be similar to people disabled later in life. However, Thalidomide survivors (as a group) are
in some respects atypical of people with disabilities: they have a similar level of education to
their peers in the general population; and at least in recent years, they have been more finan-
cially secure due to improved compensation payments and the DH Grant. Moreover, for
many any employment disadvantage (as indicated by lower rates of labour market participa-
tion) is relatively recent. Nevertheless, at this relatively late stage in life they are experiencing
exposure to the environmental and other disadvantages common to many disabled people.
This study provides further evidence of the accumulative impact of disability over peoples’
lifetimes; it demonstrates that whilst from birth conditions like Thalidomide Embryopathy are
non-progressive, they are not static; and it highlights the value of a life course perspective in
understanding the complex experience of growing older with a disability. Our paper, by
describing how impairments change over time, represents a starting point. More theoretically
work connecting this to the accumulative potential for disability is required, along with a com-
mitment to using these insights to inform a more nuanced policy, which is able to accommo-
date the fluid and changing nature of the disabling experience.
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